ReviewEClinicalMedicine2025
Implementation of the intermittent preventive treatment of malaria in school-aged children (IPTsc) in moderate and high endemic areas in Tanzania: a policy brief.
Review in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In high-transmission settings, up to 70% of school-aged children (SAC; 5-15 years) harbour malaria parasites, mostly asymptomatically. This contributes significantly to school absenteeism (13-50%) and anaemia (61%), impairing cognitive development and academic performance. Despite this burden, SAC are often excluded from malaria-targeted interventions and act as a key reservoir for transmission. Intermittent Preventive Treatment for school-aged children (IPTsc), recommended by the World Health Organization (WHO), involves administering a full antimalarial treatment course at regular intervals to prevent infection. This policy brief follows a successful clinical trial and large-scale implementation research in Tanzania that demonstrated IPTsc's operational feasibility and effectiveness. Administering Dihydroartemisinin-Piperaquine (DP) through school-based delivery proved safe, cost-effective, acceptable to communities, and led to significant reductions in malaria prevalence. These findings support IPTsc as a complementary malaria control strategy in endemic areas with moderate to high transmission. Countries with similar epidemiological profiles are encouraged to adopt IPTsc as part of their national malaria control strategies. Funding: The Global Fund, via the Ministry of Health, Tanzania (implementation research pilot of IPTsc), and Flemish Interuniversity Council (VLIR-UOS), Belgium, TEAM initiative, grant TZ2017TEA451A102 (clinical trial).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.